• Home  / 
  • Biotech
  •  /  Sangamo Therapeutics Inc (NASDAQ:SGMO) Posts Recent Highlights

Sangamo Therapeutics Inc (NASDAQ:SGMO) Posts Recent Highlights

Updating on recent highlights, Sangamo Therapeutics Inc (NASDAQ:SGMO) established global license and collaboration contract with Kite to work on next-generation cell therapies targeting cancer. It established a second collaboration and license contract with Pfizer to apply company’s ZFP-TF gene regulation platform to the advancement of potential gene treatments for C9ORF72-linked ALS and frontotemporal lobar degeneration. The company expanded and strengthened the breadth of experience and talent of the firm’s leadership team with latest key appointments.

The buzz

Sangamo Therapeutics showcased initial safety report from the first patient cured in the SB-913 Phase 1/2 CHAMPIONS trial for MPS II at the WORLD Symposium congress. It treated a third subject in the SB-525 Phase 1/2 Alta trial for hemophilia A. Together with Case Western Reserve University, the company reported the grant award of an $11 million for intended clinical trial of gene-edited T cells advanced to remove persistent HIV infection in people receiving anti-retroviral therapy.

For 2018, Sangamo reported that it plans to showcase clinical growth on core assets with preliminary clinical data readouts by this mid-year. The company will commence Phase 1/2 clinical study for ST-400 beta-thalassemia plan in early 2018; support Bioverativ in submission IND filing for sickle cell ailment; file IND application for its ST-920 Fabry disease plan.

Sangamo continue to establish gene editing standards for efficiency, specificity and precision and operationalize platform improvements. It will associate with the right partners to advance best-in-class drugs for patients. The company will set new headquarters and establish latest cGMP manufacturing facility in CA.

For the year closed December 31, 2017, Sangamo reported consolidated net loss of $54.6 million compared to $71.7 million, for the year closed December 31, 2016. Revenue came at $36.6 million for the year closed December 31, 2017, versus $19.4 million for the comparable period in 2016. The jump in revenues was mainly related to company’s hemophilia A license and collaboration agreement with Pfizer.

Click here to add a comment

Leave a comment: